Payment overview · 2025
General Payments
$100.00
6 reported records · 4 companies
Healthcare provider profile · identity verified
Michael Raichel, DO
Allopathic & Osteopathic Physicians|Family Medicine · HAZARD, KY · NPI 1932270006
Verified facts
What the public records show
CMS Open Payments records show Michael Raichel, DO received $100.00 in general payments during 2025 across 6 reported records.
ABBVIE INC. accounted for 40.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 265 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 426 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $40.17 | 40.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $29.64 | 29.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.57 | 16.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.62 | 13.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $100.00 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $40.17 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $40.17 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $29.64 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $29.64 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.57 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 426 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 265 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
50 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
60 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
265 | 37 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
76 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
426 | 45 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 839 | 139 |
| Metoprolol Tartrate | Metoprolol Tartrate | 691 | 112 |
| Atorvastatin Calcium | Atorvastatin Calcium | 675 | 113 |
| Gabapentin | Gabapentin | 646 | 99 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 646 | 134 |
| Levothyroxine Sodium | Levothyroxine Sodium | 581 | 94 |
| Lisinopril | Lisinopril | 554 | 95 |
| Potassium Chloride | Potassium Chloride | 488 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 465 | 87 |
| Furosemide | Furosemide | 444 | 91 |
| Losartan Potassium | Losartan Potassium | 441 | 81 |
| Eliquis | Apixaban | 426 | 45 |
| Buspirone Hcl | Buspirone Hcl | 420 | 68 |
| Alprazolam | Alprazolam | 419 | 55 |
| Omeprazole | Omeprazole | 381 | 56 |
| Metformin Hcl | Metformin Hcl | 361 | 72 |
| Famotidine | Famotidine | 333 | 57 |
| Duloxetine Hcl | Duloxetine Hcl | 319 | 53 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 319 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 311 | 47 |
| Simvastatin | Simvastatin | 305 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 290 | 52 |
| Montelukast Sodium | Montelukast Sodium | 287 | 52 |
| Donepezil Hcl | Donepezil Hcl | 278 | 35 |
| Farxiga | Dapagliflozin Propanediol | 265 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 264 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 245 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 245 | 34 |
| Tramadol Hcl | Tramadol Hcl | 240 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 235 | 48 |
| Citalopram Hbr | Citalopram Hydrobromide | 233 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 223 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 209 | 47 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 207 | 33 |
| Tizanidine Hcl | Tizanidine Hcl | 203 | 42 |
| Lorazepam | Lorazepam | 192 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 190 | 30 |
| Clonazepam | Clonazepam | 185 | 29 |
| Trazodone Hcl | Trazodone Hcl | 175 | 28 |
| Sertraline Hcl | Sertraline Hcl | 174 | 25 |
| Meloxicam | Meloxicam | 168 | 30 |
| Glipizide | Glipizide | 166 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 165 | 38 |
| Ondansetron Hcl | Ondansetron Hcl | 161 | 66 |
| Xarelto | Rivaroxaban | 148 | 13 |
| Carvedilol | Carvedilol | 138 | 23 |
| Ibuprofen | Ibuprofen | 136 | 36 |
| Allopurinol | Allopurinol | 133 | 24 |
| Clonidine Hcl | Clonidine Hcl | 132 | 25 |
| Mirtazapine | Mirtazapine | 132 | 17 |
| Atenolol | Atenolol | 123 | 17 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 114 | 20 |
| Finasteride | Finasteride | 105 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 104 | 16 |
| Bumetanide | Bumetanide | 99 | 12 |
| Meclizine Hcl | Meclizine Hcl | 94 | 42 |
| Risperidone | Risperidone | 93 | suppressed |
| Memantine Hcl | Memantine Hcl | 88 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 86 | 18 |
| Nifedipine Er | Nifedipine | 86 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 83 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 80 | 14 |
| Spironolactone | Spironolactone | 80 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 78 | 14 |
| Mounjaro | Tirzepatide | 77 | 13 |
| Pregabalin | Pregabalin | 77 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 76 | suppressed |
| Ozempic | Semaglutide | 76 | 17 |
| Celecoxib | Celecoxib | 74 | 14 |
| Jardiance | Empagliflozin | 72 | suppressed |
| Entresto | Sacubitril/Valsartan | 71 | suppressed |
| Xifaxan | Rifaximin | 71 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 69 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 65 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 65 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 64 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 64 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 63 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 61 | 12 |
| Synthroid | Levothyroxine Sodium | 60 | 12 |
| Levetiracetam | Levetiracetam | 59 | 14 |
| Colestipol Hcl | Colestipol Hcl | 58 | suppressed |
| Prednisone | Prednisone | 58 | 19 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 57 | suppressed |
| Glipizide Er | Glipizide | 57 | suppressed |
| Lactulose | Lactulose | 56 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 11 |
| Januvia | Sitagliptin Phosphate | 54 | suppressed |
| Baclofen | Baclofen | 53 | suppressed |
| Nitroglycerin | Nitroglycerin | 52 | 21 |
| Linzess | Linaclotide | 50 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 50 | suppressed |
| Topiramate | Topiramate | 50 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 11 |
| Amoxicillin | Amoxicillin | 49 | 30 |
| Ventolin Hfa | Albuterol Sulfate | 49 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 48 | suppressed |
| Tradjenta | Linagliptin | 48 | suppressed |
| Phenobarbital | Phenobarbital | 47 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 28 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 46 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 16 |
| Sucralfate | Sucralfate | 46 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 45 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | suppressed |
| Nystatin | Nystatin | 45 | 23 |
| Fluconazole | Fluconazole | 44 | 24 |
| Hydrocortisone | Hydrocortisone | 44 | suppressed |
| Methocarbamol | Methocarbamol | 44 | suppressed |
| Nystop | Nystatin | 44 | 11 |
| Diazepam | Diazepam | 43 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 11 |
| Trulicity | Dulaglutide | 43 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 42 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 40 | 13 |
| Lamotrigine | Lamotrigine | 40 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 38 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 37 | suppressed |
| Movantik | Naloxegol Oxalate | 37 | suppressed |
| Roflumilast | Roflumilast | 36 | suppressed |
| Ranolazine Er | Ranolazine | 35 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Aripiprazole | Aripiprazole | 34 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 34 | suppressed |
| Ezetimibe | Ezetimibe | 34 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 34 | suppressed |
| Primidone | Primidone | 34 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Verapamil Er | Verapamil Hcl | 30 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Cilostazol | Cilostazol | 29 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 29 | suppressed |
| Cephalexin | Cephalexin | 27 | 22 |
| Estradiol | Estradiol | 27 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 26 | suppressed |
| Digoxin | Digoxin | 26 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 26 | 11 |
| Acebutolol Hcl | Acebutolol Hcl | 25 | suppressed |
| Colchicine | Colchicine | 25 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 24 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 24 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 24 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 23 | suppressed |
| Latanoprost | Latanoprost | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Acyclovir | Acyclovir | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Brilinta | Ticagrelor | 21 | suppressed |
| Vascepa | Icosapent Ethyl | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Novolin R | Insulin Regular, Human | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Restasis | Cyclosporine | 19 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Constulose | Lactulose | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 18 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 18 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Calcium Acetate | Calcium Acetate | 17 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 17 | suppressed |
| Daptomycin | Daptomycin | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Ibu | Ibuprofen | 16 | suppressed |
| Lacosamide | Lacosamide | 16 | suppressed |
| Loperamide | Loperamide Hcl | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Haloperidol | Haloperidol | 15 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 15 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Dexilant | Dexlansoprazole | 14 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Gemtesa | Vibegron | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 14 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 14 | suppressed |
| Entecavir | Entecavir | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Enbrel | Etanercept | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 11 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $100.00 · 6 records | ABBVIE INC. | ELIQUIS, FARXIGA, NURTEC ODT, QULIPTA, UBRELVY, Wegovy | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error